Affimer

Last updated
The Affimer protein scaffold - showing the two loops where random peptides can be inserted to create a protein binding surface Affimer image.png
The Affimer protein scaffold – showing the two loops where random peptides can be inserted to create a protein binding surface

Affimer molecules [1] are small proteins that bind to target proteins with affinity in the nanomolar range. [2] [3] These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications. [2] [4] These affinity reagents have been optimized to increase their stability, [5] make them tolerant to a range of temperatures and pH, [6] reduce their size, and to increase their expression in E.coli and mammalian cells. [2]

Contents

Development

Affimer proteins were developed initially at the MRC Cancer Cell Unit in Cambridge then across two laboratories at the University of Leeds. [7] [8] [9] [10] Derived from the cysteine protease inhibitor family of cystatins, which function in nature as cysteine protease inhibitors, [11] [12] these 12–14 kDa proteins share the common tertiary structure of an alpha-helix lying on top of an anti-parallel beta-sheet. [13]

Affimer proteins display two peptide loops that can all be randomized to bind to desired target proteins, [5] in a similar manner to monoclonal antibodies. Stabilization of the two peptides by the protein scaffold constrains the possible conformations that the peptides can take. This increases the binding affinity and specificity compared to libraries of free peptides, though can limit the target repertoire of Affimers.

Production

Phage display libraries of 109 randomized sequences [14] are used to screen for Affimer proteins that exhibit high-specificity binding to the target protein with binding affinities in the nM range. [5] [15] [16] The ability to direct in vitro screening techniques allows the identification of specific, high affinity Affimers. In vitro screening and development also mean that the target space for Affimers is not limited by the animal immune system. Affimers are generated using recombinant systems, so their generation is more rapid and reproducible compared to the production of polyclonal antibodies. [17]

Multimeric forms Affimers have been generated and shown to yield titres in the range of 200–400 mg/L under small-scale culture using bacterial host systems. Multimeric forms of Affimers with the same target specificity provide avidity effects in target binding.

Many different tags and fusion proteins, such as fluorophores, single-stranded DNA, His, and c-Myc tags can be conjugated to Affimers. [2] [18] [19] [20] [21] [22] Specific cysteine residues can be introduced to the protein to allow thiol chemistry to uniformly orient Affimers on a solid support eg ELISA plates. [5] [15] [17] [23] [24] This flexible functionalisation of the Affimer molecule allows functionality across multiple applications and assay formats.

Properties

Affimers are recombinant proteins. As they are manufactured using recombinant bacterial production processes, the batch-to-batch consistency for Affimers is improved compared to polyclonal antibodies, overcoming some of the issues of reproducibility and security of supply. [2] [3] [17] [25] [26]

These synthetic antibodies were engineered to be stable, non-toxic, biologically neutral and contain no post-translational modifications or disulfide bridges. [7] [8] [10] Two separate loop sequences, incorporating a total of 12 to 36 amino acids, form the target interaction surface so interaction surfaces can range form 650–1000  Å. The large interaction surface results allows binding to target proteins. [5] [7] [10] [15] [17] [18] [27] [28] [29] [30]

Applications

Affimer technology has been commercialised and developed by Avacta, who are developing these affinity reagents as tools for diagnostics and as biotherapeutics.

Reagents and Diagnostics

Affimer binders have been used across a number of platforms, including ELISA, [2] [17] [31] surface plasmon resonance, [32] [31] [33] [34] affinity purification. [2] [31] [35] [36] Affimers that inhibit protein-protein interactions can be produced with the potential to express these inhibitors in mammalian cells modify signalling pathways as cell therapies. [2] [32] [33] [37] [38]

Therapeutics

The small size and stability profile of Affimers combined with their human origin confer drug-like properties. This may represent advantages over antibodies in terms of tissue penetration, for example in solid tumours where Avacta are developing PD-L1 inhibitors as alternatives to Opdivo and Yervoy, [39] though requires half life modification to prevent rapid excretion through the kidney.

Affimers can be conjugated to form multimers for the design of therapeutics. Examples include the production of multi-specific Affimer molecules to albumin binders to increase their half-life in vivo and for use as the targeting moiety in chimeric receptors or modified to carry a toxin in Affimer-drug conjugates. [16] [39] [40]

Affimers as therapeutics are in discovery and preclinical development to tackle cancer, both via CAR-T cell therapy and as immune checkpoint inhibitors. [39] [41] [42] [43] Early studies using ex vivo human samples showed low immunogenicity associated with the Affimer scaffold, at levels comparable to a marketed antibody therapeutic. [44] Furthermore, initial preclinical studies showed good efficacy and tolerability of the anti-PDL1 immuno-oncology Affimers in mice. It is anticipated that IND filing for the first Affimer therapeutic will occur in 2023. [16]

Related Research Articles

<span class="mw-page-title-main">Proteomics</span> Large-scale study of proteins

Proteomics is the large-scale study of proteins. Proteins are vital parts of living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In addition, other kinds of proteins include antibodies that protect an organism from infection, and hormones that send important signals throughout the body.

<span class="mw-page-title-main">Monoclonal antibody</span> Antibodies from clones of the same blood cell

A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.

In biochemistry, biotinylation is the process of covalently attaching biotin to a protein, nucleic acid or other molecule. Biotinylation is rapid, specific and is unlikely to disturb the natural function of the molecule due to the small size of biotin. Biotin binds to streptavidin and avidin with an extremely high affinity, fast on-rate, and high specificity, and these interactions are exploited in many areas of biotechnology to isolate biotinylated molecules of interest. Biotin-binding to streptavidin and avidin is resistant to extremes of heat, pH and proteolysis, making capture of biotinylated molecules possible in a wide variety of environments. Also, multiple biotin molecules can be conjugated to a protein of interest, which allows binding of multiple streptavidin, avidin or neutravidin protein molecules and increases the sensitivity of detection of the protein of interest. There is a large number of biotinylation reagents available that exploit the wide range of possible labelling methods. Due to the strong affinity between biotin and streptavidin, the purification of biotinylated proteins has been a widely used approach to identify protein-protein interactions and post-translational events such as ubiquitylation in molecular biology.

<span class="mw-page-title-main">Phage display</span> Biological technique to evolve proteins using bacteriophages

Phage display is a laboratory technique for the study of protein–protein, protein–peptide, and protein–DNA interactions that uses bacteriophages to connect proteins with the genetic information that encodes them. In this technique, a gene encoding a protein of interest is inserted into a phage coat protein gene, causing the phage to "display" the protein on its outside while containing the gene for the protein on its inside, resulting in a connection between genotype and phenotype. The proteins that the phages are displaying can then be screened against other proteins, peptides or DNA sequences, in order to detect interaction between the displayed protein and those of other molecules. In this way, large libraries of proteins can be screened and amplified in a process called in vitro selection, which is analogous to natural selection.

<span class="mw-page-title-main">Aptamer</span> Oligonucleotide or peptide molecules that bind specific targets

Aptamers are short sequences of artificial DNA, RNA, XNA, or peptide that bind a specific target molecule, or family of target molecules. They exhibit a range of affinities, with variable levels of off-target binding and are sometimes classified as chemical antibodies. Aptamers and antibodies can be used in many of the same applications, but the nucleic acid-based structure of aptamers, which are mostly oligonucleotides, is very different from the amino acid-based structure of antibodies, which are proteins. This difference can make aptamers a better choice than antibodies for some purposes.

<span class="mw-page-title-main">Avidin</span> Type of protein

Avidin is a tetrameric biotin-binding protein produced in the oviducts of birds, reptiles and amphibians and deposited in the whites of their eggs. Dimeric members of the avidin family are also found in some bacteria. In chicken egg white, avidin makes up approximately 0.05% of total protein (approximately 1800 μg per egg). The tetrameric protein contains four identical subunits (homotetramer), each of which can bind to biotin (Vitamin B7, vitamin H) with a high degree of affinity and specificity. The dissociation constant of the avidin-biotin complex is measured to be KD ≈ 10−15 M, making it one of the strongest known non-covalent bonds.

Bacterial display is a protein engineering technique used for in vitro protein evolution. Libraries of polypeptides displayed on the surface of bacteria can be screened using flow cytometry or iterative selection procedures (biopanning). This protein engineering technique allows us to link the function of a protein with the gene that encodes it. Bacterial display can be used to find target proteins with desired properties and can be used to make affinity ligands which are cell-specific. This system can be used in many applications including the creation of novel vaccines, the identification of enzyme substrates and finding the affinity of a ligand for its target protein.

<span class="mw-page-title-main">Digoxigenin</span> Chemical compound

Digoxigenin (DIG) is a steroid found exclusively in the flowers and leaves of the plants Digitalis purpurea, Digitalis orientalis and Digitalis lanata (foxgloves), where it is attached to sugars, to form the glycosides.

<span class="mw-page-title-main">Gp41</span> Subunit of the envelope protein complex of retroviruses

Gp41 also known as glycoprotein 41 is a subunit of the envelope protein complex of retroviruses, including human immunodeficiency virus (HIV). Gp41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. As a result of its importance in host cell infection, it has also received much attention as a potential target for HIV vaccines.

<span class="mw-page-title-main">Cystatin</span> Group of endogenous cysteine proteinase inhibitors

The cystatins are a family of cysteine protease inhibitors which share a sequence homology and a common tertiary structure of an alpha helix lying on top of an anti-parallel beta sheet. The family is subdivided as described below.

<span class="mw-page-title-main">Immunoproteomics</span> Study of large set of protein

Immunoproteomics is the study of large sets of proteins (proteomics) involved in the immune response.

<span class="mw-page-title-main">Meir Wilchek</span> Israeli biochemist (born 1935)

Meir Wilchek is an Israeli biochemist. He is a professor at the Weizmann Institute of Science.

<span class="mw-page-title-main">CST1</span> Protein-coding gene in the species Homo sapiens

Cystatin-SN is a protein that in humans is encoded by the CST1 gene.

<span class="mw-page-title-main">Scorpion toxin</span>

Scorpion toxins are proteins found in the venom of scorpions. Their toxic effect may be mammal- or insect-specific and acts by binding with varying degrees of specificity to members of the Voltage-gated ion channel superfamily; specifically, voltage-gated sodium channels, voltage-gated potassium channels, and Transient Receptor Potential (TRP) channels. The result of this action is to activate or inhibit the action of these channels in the nervous and cardiac organ systems. For instance, α-scorpion toxins MeuNaTxα-12 and MeuNaTxα-13 from Mesobuthus eupeus are neurotoxins that target voltage-gated Na+ channels (Navs), inhibiting fast inactivation. In vivo assays of MeuNaTxα-12 and MeuNaTxα-13 effects on mammalian and insect Navs show differential potency. These recombinants exhibit their preferential affinity for mammalian and insect Na+ channels at the α-like toxins' active site, site 3, in order to inactivate the cell membrane depolarization faster[6]. The varying sensitivity of different Navs to MeuNaTxα-12 and MeuNaTxα-13 may be dependent on the substitution of a conserved Valine residue for a Phenylalanine residue at position 1630 of the LD4:S3-S4 subunit or due to various changes in residues in the LD4:S5-S6 subunit of the Navs. Ultimately, these actions can serve the purpose of warding off predators by causing pain or to subdue predators.

<span class="mw-page-title-main">Anti–citrullinated protein antibody</span> Autoantibodies

Anti-citrullinated protein antibodies (ACPAs) are autoantibodies that are directed against peptides and proteins that are citrullinated. They are present in the majority of patients with rheumatoid arthritis. Clinically, cyclic citrullinated peptides (CCP) are frequently used to detect these antibodies in patient serum or plasma.

Affibody molecules are small, robust proteins engineered to bind to a large number of target proteins or peptides with high affinity, imitating monoclonal antibodies, and are therefore a member of the family of antibody mimetics. Affibody molecules are used in biochemical research and are being developed as potential new biopharmaceutical drugs. These molecules can be used for molecular recognition in diagnostic and therapeutic applications.

Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens, but that are not structurally related to antibodies. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa.

<span class="mw-page-title-main">Monobody</span> Synthetic binding proteins

Monobodies are synthetic binding proteins constructed using a fibronectin type III domain (FN3) as a molecular scaffold. Specifically, this class of binding proteins are built upon a diversified library of the 10th FN3 domain of human fibronectin. Monobodies are a simple and robust alternative to antibodies for creating target-binding proteins. The hybrid term monobody was coined in 1998 by the Koide group who published the first paper demonstrating the monobody concept using the tenth FN3 domain of human fibronectin.

<span class="mw-page-title-main">Antibody–drug conjugate</span> Class of biopharmaceutical drugs

Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.

Synthetic antibodies are affinity reagents generated entirely in vitro, thus completely eliminating animals from the production process. Synthetic antibodies include recombinant antibodies, nucleic acid aptamers and non-immunoglobulin protein scaffolds. As a consequence of their in vitro manufacturing method the antigen recognition site of synthetic antibodies can be engineered to any desired target and may extend beyond the typical immune repertoire offered by natural antibodies. Synthetic antibodies are being developed for use in research, diagnostic and therapeutic applications. Synthetic antibodies can be used in all applications where traditional monoclonal or polyclonal antibodies are used and offer many inherent advantages over animal-derived antibodies, including comparatively low production costs, reagent reproducibility and increased affinity, specificity and stability across a range of experimental conditions.

References

  1. ↑ Proprietary name, owned by Avacta
  2. 1 2 3 4 5 6 7 8 Tiede C, Bedford R, Heseltine SJ, Smith G, Wijetunga I, Ross R, et al. (June 2017). "Affimer proteins are versatile and renewable affinity reagents". eLife. 6. doi: 10.7554/elife.24903 . PMC   5487212 . PMID   28654419.
  3. 1 2 Klont F, Hadderingh M, Horvatovich P, Ten Hacken NH, Bischoff R (August 2018). "Affimers as an Alternative to Antibodies in an Affinity LC-MS Assay for Quantification of the Soluble Receptor of Advanced Glycation End-Products (sRAGE) in Human Serum". Journal of Proteome Research. 17 (8): 2892–2899. doi:10.1021/acs.jproteome.8b00414. PMC   6079930 . PMID   30005571.
  4. ↑ "Antibody Alternatives". The Scientist Magazine®. Retrieved 2018-10-18.
  5. 1 2 3 4 5 Sharma R, Deacon SE, Nowak D, George SE, Szymonik MP, Tang AA, Tomlinson DC, Davies AG, McPherson MJ, Wälti C (June 2016). "Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity". Biosensors & Bioelectronics. 80: 607–613. doi:10.1016/j.bios.2016.02.028. PMC   4785862 . PMID   26897263.
  6. ↑ Rawlings AE, Bramble JP, Tang AA, Somner LA, Monnington AE, Cooke DJ, McPherson MJ, Tomlinson DC, Staniland SS (October 2015). "Phage display selected magnetite interacting Adhirons for shape controlled nanoparticle synthesis". Chemical Science. 6 (10): 5586–5594. doi:10.1039/C5SC01472G. PMC   5949846 . PMID   29861896.
  7. 1 2 3 Woodman R, Yeh JT, Laurenson S, Ko Ferrigno P (October 2005). "Design and validation of a neutral protein scaffold for the presentation of peptide aptamers". Journal of Molecular Biology. 352 (5): 1118–33. doi:10.1016/j.jmb.2005.08.001. PMID   16139842.
  8. 1 2 Hoffmann T, Stadler LK, Busby M, Song Q, Buxton AT, Wagner SD, Davis JJ, Ko Ferrigno P (May 2010). "Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant". Protein Engineering, Design & Selection. 23 (5): 403–13. doi:10.1093/protein/gzq012. PMC   2851446 . PMID   20179045.
  9. ↑ Stadler LK, Hoffmann T, Tomlinson DC, Song Q, Lee T, Busby M, Nyathi Y, Gendra E, Tiede C, Flanagan K, Cockell SJ, Wipat A, Harwood C, Wagner SD, Knowles MA, Davis JJ, Keegan N, Ferrigno PK (September 2011). "Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant". Protein Engineering, Design & Selection. 24 (9): 751–63. doi:10.1093/protein/gzr019. PMID   21616931.
  10. 1 2 3 Tiede C, Tang AA, Deacon SE, Mandal U, Nettleship JE, Owen RL, George SE, Harrison DJ, Owens RJ, Tomlinson DC, McPherson MJ (May 2014). "Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications". Protein Engineering, Design & Selection. 27 (5): 145–55. doi:10.1093/protein/gzu007. PMC   4000234 . PMID   24668773.
  11. ↑ Turk V, Stoka V, Turk D (May 2008). "Cystatins: biochemical and structural properties, and medical relevance". Frontiers in Bioscience. 13 (13): 5406–20. doi: 10.2741/3089 . PMID   18508595.
  12. ↑ Kondo H, Abe K, Emori Y, Arai S (January 1991). "Gene organization of oryzacystatin-II, a new cystatin superfamily member of plant origin, is closely related to that of oryzacystatin-I but different from those of animal cystatins". FEBS Letters. 278 (1): 87–90. doi: 10.1016/0014-5793(91)80090-p . PMID   1993479. S2CID   40605067.
  13. ↑ Turk V, Bode W (July 1991). "The cystatins: protein inhibitors of cysteine proteinases". FEBS Letters. 285 (2): 213–9. doi:10.1016/0014-5793(91)80804-C. PMID   1855589. S2CID   40444629.
  14. ↑ Arrata I, Barnard A, Tomlinson DC, Wilson AJ (March 2017). "Interfacing native and non-native peptides: using Affimers to recognise α-helix mimicking foldamers" (PDF). Chemical Communications. 53 (19): 2834–2837. doi:10.1039/c6cc09395g. PMID   28217789.
  15. 1 2 3 Zhurauski P, Arya SK, Jolly P, Tiede C, Tomlinson DC, Ko Ferrigno P, Estrela P (June 2018). "Sensitive and selective Affimer-functionalised interdigitated electrode-based capacitive biosensor for Her4 protein tumour biomarker detection" (PDF). Biosensors & Bioelectronics. 108: 1–8. doi:10.1016/j.bios.2018.02.041. PMID   29482002. S2CID   3549374.
  16. 1 2 3 Basran A, Stanley E (2018-07-01). "Abstract 3776: Generation and formatting of an Affimer® biotherapeutic for the inhibition of the PD-L1/PD-1 pathway: Proof of concept in mouse". Cancer Research. 78 (13 Supplement): 3776. doi:10.1158/1538-7445.AM2018-3776. ISSN   0008-5472. S2CID   81376936.
  17. 1 2 3 4 5 Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC, Xu W (August 2017). "Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3". Scientific Reports. 7 (1): 9608. Bibcode:2017NatSR...7.9608X. doi:10.1038/s41598-017-10083-w. PMC   5575301 . PMID   28852111.
  18. 1 2 Schlichthaerle T, Eklund AS, Schueder F, Strauss MT, Tiede C, Curd A, Ries J, Peckham M, Tomlinson DC, Jungmann R (August 2018). "Site-Specific Labeling of Affimers for DNA-PAINT Microscopy" (PDF). Angewandte Chemie. 57 (34): 11060–11063. doi:10.1002/anie.201804020. PMID   29873161. S2CID   46950252.
  19. ↑ Bedford R, Tiede C, Hughes R, Curd A, McPherson MJ, Peckham M, Tomlinson DC (August 2017). "Alternative reagents to antibodies in imaging applications". Biophysical Reviews. 9 (4): 299–308. doi:10.1007/s12551-017-0278-2. PMC   5578921 . PMID   28752365.
  20. ↑ Lopata A, Hughes R, Tiede C, Heissler SM, Sellers JR, Knight PJ, Tomlinson D, Peckham M (April 2018). "Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells". Scientific Reports. 8 (1): 6572. Bibcode:2018NatSR...8.6572L. doi:10.1038/s41598-018-24953-4. PMC   5920084 . PMID   29700342.
  21. ↑ Wang W, Guo Y, Tiede C, Chen S, Kopytynski M, Kong Y, Kulak A, Tomlinson D, Chen R, McPherson M, Zhou D (May 2017). "Ultraefficient Cap-Exchange Protocol To Compact Biofunctional Quantum Dots for Sensitive Ratiometric Biosensing and Cell Imaging". ACS Applied Materials & Interfaces. 9 (18): 15232–15244. doi:10.1021/acsami.6b13807. PMC   5432960 . PMID   28421739.
  22. ↑ Fisher MJ, Williamson DJ, Burslem GM, Plante JP, Manfield IW, Tiede C, Ault JR, Stockley PG, Plein S, Maqbool A, Tomlinson DC, Foster R, Warriner SL, Bon RS (December 2015). "Trivalent Gd-DOTA reagents for modification of proteins". RSC Advances. 5 (116): 96194–96200. Bibcode:2015RSCAd...596194F. doi:10.1039/c5ra20359g. PMC   4786947 . PMID   27019702.
  23. ↑ Weckman NE, McRae C, Ko Ferrigno P, Seshia AA (October 2016). "Comparison of the specificity and affinity of surface immobilised Affimer binders using the quartz crystal microbalance". The Analyst. 141 (22): 6278–6286. Bibcode:2016Ana...141.6278W. doi:10.1039/c6an01602b. PMID   27704086.
  24. ↑ Koutsoumpeli E, Tiede C, Murray J, Tang A, Bon RS, Tomlinson DC, Johnson S (March 2017). "Antibody Mimetics for the Detection of Small Organic Compounds Using a Quartz Crystal Microbalance". Analytical Chemistry. 89 (5): 3051–3058. doi:10.1021/acs.analchem.6b04790. PMID   28192970.
  25. ↑ "Anti-idiotypic binders for Trastuzumab validated in regulatory bioanalysis assay in collaboration with Covance". Avacta. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  26. ↑ "Development and validation of anti-idiotypic Affmers to trastuzumab in a pharmacokinetic assay | Avacta". www.avacta.com. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  27. ↑ Davis JJ, Tkac J, Laurenson S, Ko Ferrigno P (February 2007). "Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold". Analytical Chemistry. 79 (3): 1089–96. doi:10.1021/ac061863z. PMID   17263340.
  28. ↑ Davis JJ, Tkac J, Humphreys R, Buxton AT, Lee TA, Ko Ferrigno P (May 2009). "Peptide aptamers in label-free protein detection: 2. Chemical optimization and detection of distinct protein isoforms". Analytical Chemistry. 81 (9): 3314–20. doi:10.1021/ac802513n. PMID   19320493.
  29. ↑ "Affimer binders improve diagnostic assay performance for C.difficile detection". Avacta. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  30. ↑ "Development and characterisation of Affimer binders to 4 leading therapeutic antibodies | Avacta". www.avacta.com. Archived from the original on 2018-10-19. Retrieved 2018-10-19.
  31. 1 2 3 "Avacta Scientist Dr Geoff Platt presents Affimer data in webinar | Avacta". www.avacta.com. Archived from the original on 2018-10-22. Retrieved 2018-10-22.
  32. 1 2 Robinson JI, Baxter EW, Owen RL, Thomsen M, Tomlinson DC, Waterhouse MP, Win SJ, Nettleship JE, Tiede C, Foster RJ, Owens RJ, Fishwick CW, Harris SA, Goldman A, McPherson MJ, Morgan AW (January 2018). "Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action". Proceedings of the National Academy of Sciences of the United States of America. 115 (1): E72–E81. doi: 10.1073/pnas.1707856115 . PMC   5776790 . PMID   29247053.
  33. 1 2 Michel MA, Swatek KN, Hospenthal MK, Komander D (October 2017). "Ubiquitin Linkage-Specific Affimers Reveal Insights into K6-Linked Ubiquitin Signaling". Molecular Cell. 68 (1): 233–246.e5. doi:10.1016/j.molcel.2017.08.020. PMC   5640506 . PMID   28943312.
  34. ↑ Johnson A, Song Q, Ko Ferrigno P, Bueno PR, Davis JJ (August 2012). "Sensitive affimer and antibody based impedimetric label-free assays for C-reactive protein". Analytical Chemistry. 84 (15): 6553–60. doi:10.1021/ac300835b. PMID   22789061.
  35. ↑ "Affimer® reagents facilitate affinity chromatography purification". www.drugtargetreview.com. Retrieved 2018-10-22.
  36. ↑ Pechlivani, Nikoletta; Kearney, Katherine J.; Tiede, Christian; Cheah, Ramsah; Phoenix, Fladia; Ponnambalam, Sreenivasan; Ault, James R.; McPherson, Michael J.; Tomlinson, Darren C.; Ajjan, Ramzi A. (2022-05-01). "Affinity purification of fibrinogen using an Affimer column". Biochimica et Biophysica Acta (BBA) - General Subjects. 1866 (5): 130115. doi: 10.1016/j.bbagen.2022.130115 . ISSN   0304-4165. PMID   35240235. S2CID   247199635.
  37. ↑ Kyle HF, Wickson KF, Stott J, Burslem GM, Breeze AL, Tiede C, Tomlinson DC, Warriner SL, Nelson A, Wilson AJ, Edwards TA (October 2015). "Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies". Molecular BioSystems. 11 (10): 2738–49. doi: 10.1039/c5mb00284b . PMID   26135796.
  38. ↑ Heidelberger JB, Voigt A, Borisova ME, Petrosino G, Ruf S, Wagner SA, Beli P (April 2018). "Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function". EMBO Reports. 19 (4): e44754. doi:10.15252/embr.201744754. PMC   5891417 . PMID   29467282.
  39. 1 2 3 "Interview with Amrik Basran at Avacta Life Sciences". Drug Target Review.
  40. ↑ "TMAC Affimer Drug Conjugates". Avacta. Archived from the original on 2018-10-22. Retrieved 2018-10-22.
  41. ↑ Mulligan, Tom. "Avacta and Memorial Sloan Kettering Cancer Center in cell therapy research collaboration". Archived from the original on 2022-07-03. Retrieved 2018-10-22.
  42. ↑ "Pipeline | Avacta". www.avacta.com. Retrieved 2018-10-22.
  43. ↑ King R, Tiede C, Simmons K, Fishwick C, Tomlinson D, Ajjan R (February 2015). "Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes". Lancet. 385 (Suppl 1): S57. doi:10.1016/s0140-6736(15)60372-5. PMID   26312879. S2CID   35622552.
  44. ↑ "Affimer Technology: Results of PBMC Immunogenicity Testing". Avacta. Archived from the original on 2018-10-22. Retrieved 2018-10-22.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.